View in EDS HTML Full Text PDF Full Text

Efficacy and safety of the ustekinumab biosimilar ABP 654 in patients with moderate-to-severe plaque psoriasis: a randomized double-blinded active-controlled comparative clinical study over 52 weeks.

Saved in:
Bibliographic Details
Title: Efficacy and safety of the ustekinumab biosimilar ABP 654 in patients with moderate-to-severe plaque psoriasis: a randomized double-blinded active-controlled comparative clinical study over 52 weeks.
Authors: Blauvelt A; Oregon Medical Research Center, Portland, OR, USA., Papp K; Alliance Clinical Trials Probity Medical Research, Waterloo, ON, Canada.; Department of Medicine, Division of Dermatology, University of Toronto, Toronto, ON, Canada., Trivedi M; Amgen Inc., Thousand Oaks, CA, USA., Barragan C; Amgen Inc., Thousand Oaks, CA, USA., Chow V; Amgen Inc., Thousand Oaks, CA, USA., Mytych DT; Amgen Inc., Thousand Oaks, CA, USA., Yamauchi P; Dermatology Institute and Skin Care Center, Inc. Clinical Science Institute, Santa Monica, CA, USA., Crowley J; Bakersfield Dermatology and Skin Cancer Medical Group, Bakersfield, CA, USA., Franklin J; Amgen Inc., Thousand Oaks, CA, USA.
Source: The British journal of dermatology [Br J Dermatol] 2025 Apr 28; Vol. 192 (5), pp. 826-836.
Publication Type: Journal Article; Randomized Controlled Trial; Comparative Study; Multicenter Study
Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 0004041 Publication Model: Print Cited Medium: Internet ISSN: 1365-2133 (Electronic) Linking ISSN: 00070963 NLM ISO Abbreviation: Br J Dermatol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39442018
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Efficacy and safety of the ustekinumab biosimilar ABP 654 in patients with moderate-to-severe plaque psoriasis: a randomized double-blinded active-controlled comparative clinical study over 52 weeks.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Blauvelt+A%22">Blauvelt A</searchLink>; Oregon Medical Research Center, Portland, OR, USA.<br /><searchLink fieldCode="AU" term="%22Papp+K%22">Papp K</searchLink>; Alliance Clinical Trials Probity Medical Research, Waterloo, ON, Canada.; Department of Medicine, Division of Dermatology, University of Toronto, Toronto, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Trivedi+M%22">Trivedi M</searchLink>; Amgen Inc., Thousand Oaks, CA, USA.<br /><searchLink fieldCode="AU" term="%22Barragan+C%22">Barragan C</searchLink>; Amgen Inc., Thousand Oaks, CA, USA.<br /><searchLink fieldCode="AU" term="%22Chow+V%22">Chow V</searchLink>; Amgen Inc., Thousand Oaks, CA, USA.<br /><searchLink fieldCode="AU" term="%22Mytych+DT%22">Mytych DT</searchLink>; Amgen Inc., Thousand Oaks, CA, USA.<br /><searchLink fieldCode="AU" term="%22Yamauchi+P%22">Yamauchi P</searchLink>; Dermatology Institute and Skin Care Center, Inc. Clinical Science Institute, Santa Monica, CA, USA.<br /><searchLink fieldCode="AU" term="%22Crowley+J%22">Crowley J</searchLink>; Bakersfield Dermatology and Skin Cancer Medical Group, Bakersfield, CA, USA.<br /><searchLink fieldCode="AU" term="%22Franklin+J%22">Franklin J</searchLink>; Amgen Inc., Thousand Oaks, CA, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220004041%22">The British journal of dermatology</searchLink> [Br J Dermatol] 2025 Apr 28; Vol. 192 (5), pp. 826-836.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial; Comparative Study; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Oxford+University+Press%22">Oxford University Press </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>0004041 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1365-2133 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200070963%22">00070963 </searchLink><i>NLM ISO Abbreviation: </i>Br J Dermatol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39442018
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1093/bjd/ljae402
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 826
    Titles:
      – TitleFull: Efficacy and safety of the ustekinumab biosimilar ABP 654 in patients with moderate-to-severe plaque psoriasis: a randomized double-blinded active-controlled comparative clinical study over 52 weeks.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Blauvelt A
      – PersonEntity:
          Name:
            NameFull: Papp K
      – PersonEntity:
          Name:
            NameFull: Trivedi M
      – PersonEntity:
          Name:
            NameFull: Barragan C
      – PersonEntity:
          Name:
            NameFull: Chow V
      – PersonEntity:
          Name:
            NameFull: Mytych DT
      – PersonEntity:
          Name:
            NameFull: Yamauchi P
      – PersonEntity:
          Name:
            NameFull: Crowley J
      – PersonEntity:
          Name:
            NameFull: Franklin J
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 28
              M: 04
              Text: 2025 Apr 28
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1365-2133
          Numbering:
            – Type: volume
              Value: 192
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: The British journal of dermatology
              Type: main
ResultId 1